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GSK-3 protein and the 
heart: friend or foe?
argue strongly that its inhibition may also become an important 
future drug target in this field. 
A centrAl role for GSK-3 in inSulin                   
SiGnAllinG
Whole-body glucose homeostasis is a continuous process and a 
function of the production of glucose by the liver and the peri-
pheral disposal of glucose, primarily by skeletal muscle. These two 
processes are regulated by several endocrine factors, the most 
important of which are insulin and glucagon, produced by the 
pancreatic β− and α−cells respectively.   
Hepatic glucose production is mediated by both glycogenolysis 
and gluconeogenesis.  When there is increased glucose demand by 
peripheral tissue, e.g. muscle contraction during exercise, the liver 
must produce glucose accordingly to prevent development of 
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GSK-3 inhibition AS future druG tArGet          
Glycogen synthase kinase-3 (GSK-3) was identified in the early 
1980s as an enzyme involved in the control of glycogen meta-
bolism, and extensively researched, especially in the context of the 
metabolic actions of insulin.(1) Currently, interest in this kinase has 
flared because of the development of new generations of inhibitors 
with specific clinical implications, especially in the potential of these 
inhibitors to treat diseases that currently have significant limitations 
in therapeutic treatments, e.g. type 2 diabetes, Alzheimer’s disease, 
stroke and bipolar- and mood disorders.(2)  The prototype of a 
GSK-3 inhibitor is lithium, although the mechanism of this inhibition 
is not understood.(69)  There is no clinical data available at present 
on the inhibition of GSK-3, but preclinical data supports an 
important future role. Scant preclinical data is available in the field 
of heart research, but, as this review has tried to summarise, the 
available evidence, as well as the multiplicity of actions of this kinase, 
Metabolic syndrome manifesting as obesity, insulin resist-
ance and type 2 diabetes mellitus is currently pandemic. 
each of these, in its own right, is strongly related to the 
development of cardiovascular disease. the cardiomyo- 
pathy associated with these disorders is characterised by 
curtailed glucose uptake and utilisation, elevated risk of 
damage after ischaemia and contractile dysfunction.  current 
research have indicated that the serine/threonine kinase, 
glycogen synthase kinase 3 (GSK-3), may play a central role 
in the development of all these dysfunctions. the develop-
ment of new generations of inhibitors of this kinase, has 
renewed interest in its utilisation as therapeutic target. 
this review has therefore focused on the role of GSK-3 in 
the development of the obesity-related cardiomyopathy and 
has highlighted and discussed the detrimental as well as 
beneficial effects of the GSK-3 inhibitors that are currently 
available. We have discussed the different roleplayers such as 
the insulin signalling pathway, modulation of apoptosis and 
mitochondrial function, SercA2 expression and regulation 
of the development of hypertrophy in the context of GSK-3 




















hypoglycemia. These processes are governed by a decrease in insu-
lin secretion and an increase in glucagon secretion, as well as by 
changes in adrenalin and cortisol secretion. 
As a continuously contracting muscle, the heart uses between 3.5 
and 5 kg of ATP per day.   To produce this, glucose, fatty acids, amino 
acids and ketones are readily used as fuel substrates(3). Muscle 
glucose utilisation is acutely regulated by insulin (Figure 1).  This is 
accomplished through a series of events initiated by binding of 
insulin to the α-subunit of the insulin receptor, leading to auto-
phosphorylation of the membrane-spanning β-subunit. The acti-
vated insulin receptor, a proto-type tyrosine kinase enzyme,  leads 
to the sequential activation of a kinase cascade involving insulin 
receptor subtstrate proteins (IRSs), PI-3-Kinase (phosphatidylino-
sitol-3-kinase) and protein kinase B/Akt.  Activation of PKB/Akt is 
a prerequisite for the translocation of the insulin regulated glucose 
transporter, glut 4, from intracellular storage vesicles to the cell 
membrane to facilitate glucose uptake.(4) Glut 4 is the major 
transporter responsible for uptake of glucose into heart muscle 
after stimulation with insulin or after anoxia or ischaemia of the 
muscle.  Glut 1, previously taken to be responsible for basal glucose 
uptake, is apparently more concentrated in the endothelial cells 
of the microvasculature of the heart and does not respond to 
insulin with translocation from one compartment to another.(5) 
On cell entry, glucose can either be shunted into glycolytic path-
ways and metabolised to pyruvate or converted to glycogen via 
activation of the enzyme glycogen synthase (GS). Stimulation of 
muscle cells with insulin activates pathways that enhance glycogen 
formation. PKB/Akt was initially described as the kinase leading to 
activation of GS after insulin stimulation via phosphorylation of 
glycogen synthase kinase-3.(6)   
The mammalian heart expresses 2 isoforms of glycogen synthase 
kinase-3 (GSK-3). GSK-3α and GSK-3β exhibit a high degree of 
sequence similarity and have molecular masses of 51 and 47 kDa 
fiGure 1:  A general schematic representation of the signal transduction pathways involved in GSK-3 activity. 
IR: insulin receptor, IRS-1: insulin receptor substrate-1, PI-3-Kinase: phosphatidyl inositol-3-kinase, PKB/Akt: protein kinase B, GSK-3: glycogen synthase kinase-3, GS: glycogen synthase, NFAT: nuclear 
































respectively.  PKB/Akt phosphorylates both isoforms of GSK-3 on 
Ser21 and Ser9 respectively. GSK-3 is constitutively active in resting 
cells and its activity is negatively regulated by this phosphorylation.(7) 
As reviewed by Sugden et al.,(8) this negative regulation can also 
be accomplished by other kinases such as ribosomal S6 kinase, 
(S6K), p90-ribosomal S6 kinase (RSK), the mitogen and stress 
activated protein kinases (MSK’s), serum and glucocorticoid-
regulated kinase (SGK’s) as well as cAMP-dependent protein 
kinase, PKA. All of these signalling pathways are highly relevant in 
cardiovascular physiology and pathophysiology. In vivo, inhibition 
of GSK-3 and activation of GS by insulin, is mainly regulated by 
the pathway involving PI-3-Kinase and PKB/Akt.(9) Besides glycogen 
synthesis, the expression and activation of GSK-3 protein impacts 
on diverse cellular processes such as glucose transport, gene 
transcription, cell differentiation, cell survival or –death (apoptosis), 
as well as muscle contractility.(10)
inSulin reSiStAnce                                                     
The pre-dominant role of insulin is the maintenance of whole 
body glucose homeostasis. Although this has been known for 
many years, it was not until 1949 that the ability of insulin to 
stimulate glucose uptake was experimentally demonstrated.(11) 
PKB/Akt, as mediator of the metabolic effects of insulin, promotes 
glucose uptake in vascular-, skeletal muscle and adipose tissue.(12) 
It is well-established that insulin stimulates glucose uptake also in 
heart muscle. Using 2-deoxy-D-3[H] - glucose (2DG) uptake in 
primary neonatal(13) or adult(14) rat cardiomyocytes as a readout 
of insulin response, it was demonstrated that insulin stimulation 
leads to increased 2DG uptake. Cardiac glucose uptake is depend-
ent on the transmembrane glucose gradient as well the content 
of sarcolemmal glucose transporters, glut 1 and glut 4,(15,16) with glut 
4 considered to be the principal contributor to the regulation of 
glucose uptake by insulin.(17)  Insulin via PKB/Akt activation induces 
the translocation of glut 4 from the intracellular storage vesicles to 
the sarcolemmal membrane to facilitate glucose entry.(17,18) 
Metabolic syndrome is a cluster of metabolic disturbances that 
together define a progressive condition associated with develop-
ment of type 2 diabetes mellitus and cardiovascular disease.(19-21)  
It is estimated that metabolic syndrome affects approximately one 
quarter of the population in developed countries.(22) The National 
Cholesterol Education Programme’s Adult Treatment Panel III 
(NCEP: ATP III) and the European Group for the Study of Insulin 
Resistance, identified central–abdominal obesity, atherogenic dys-
lipidaemia (hypertriglyceridaemia and reduced high-density lipo-
protein-cholesterol), raised blood pressure, insulin resistance and 
glucose intolerance as components for metabolic syndrome.(23,24) 
Furthermore, it has been reported that each component of the 
syndrome may be considered as independent risk factors for 
cardiovascular disease.(24) Over the past two decades, the number 
of people with metabolic syndrome has increased at an alarming 
rate. This increase is associated with the global epidemic of both 
obesity and diabetes.(25)
The inability of cells to respond appropriately to a certain level of 
insulin, is termed insulin resistance.(26) This is a defect associated 
with a variety of disorders including metabolic syndrome, athero-
sclerosis, hypertension, dyslipidaemia, type 2 diabetes and heart 
failure.  Increased cardiovascular risk is central to all these disorders 
and has been ascribed by some to the elevated plasma insulin levels 
that accompany insulin resistance.(27) However, the United Kingdom 
Prospective Diabetes Study could not detect a correlation between 
higher cardiovascular risk and elevated insulin levels.(28) Alternatively, 
obesity, with the accompanying elevated plasma free fatty acid 
levels, has been identified as probable cause of myocardial insulin 
resistance and is recognised as an independent risk factor of 
cardiovascular disease.(29,30) 
The insulin resistant state is characterised by impaired signalling via 
the IRS-1/PI-3-Kinase/PKB/Akt-pathway. Reduced insulin receptor- 
and IRS-1 tyrosine phosphorylation(31,32) and IRS-1 associated PI-3-
Kinase activity(31) have been reported in adipocytes while lower 
PKB/Akt activity(14) was found in the rat heart. In animal models of 
obesity and type 2 diabetes(13) as well as in humans,(33,34) attenuated 
muscle glucose transport has been documented, coupled to 
ineffective attenuation of hepatic glucose production. In addition, 
several studies have drawn negative correlations between GSK-3 
activity, glucose uptake and muscle glycogen content.(35,36)  Cur- 
rently, there is no evidence for genetic mutations in either one of 




















the two GSK-3 genes associated with the development of type 2 
diabetes mellitus(37) but there are studies demonstrating upregu-
lation of expression and higher activity of GSK-3 protein in skeletal 
muscle of type 2 diabetic patients and in adipose tissues of 
obese diabetic rodent models.(38,39) In addition, it was shown that 
inhibition of GSK-3 improves insulin action in skeletal muscle of 
obese, insulin resistant rodents.(40,41) The potential benefits of 
GSK-3 inhibition for the treatment of insulin resistance and type 2 
diabetes, as demonstrated in different animal models, is elegantly 
reviewed by Wagman et al.(42) In view of the vast amount of 
literature on this subject, this review will focus mainly on the 
cardiovascular effects of GSK-3 inhibition with special reference to 
insulin resistance.
the heArt in obeSity And inSulin                          
reSiStAnce
Studies have suggested that several agents are able to induce 
myocardial insulin resistance by activation of serine/threonine 
kinases that phosphorylate IRS-1 and inhibit its function.(43) These 
agents include tumor necrosis factor α (TNFα),(44) free fatty 
acids,(33) cellular stress,(43) angiotensin II(45) and hyperinsulinemia.(46) 
Insulin itself may also stimulate serine kinases that promote phos-
phorylation of IRS-1.(47)  According to Gual et al., the inhibition of 
IRS-1 function may represent the unifying mechanistic link be- 
tween all factors involved in insulin resistance. GSK-3 protein, in 
its active state, also has the ability to phosphorylate IRS-1 on 2 
serine residues (Ser307 and 332).(43)  This phosphorylation by GSK-
3 is associated with downregulation of signalling via IRS-1(48) and 
may potentially exacerbate insulin resistance and compromise 
glucose uptake as it is associated with impaired tyrosine phos-
phorylation of IRS-1 and decreased PI-3-Kinase activation.(49) The 
importance of this observation is underscored by the work of 
Rao et al.(50) showing enhanced myocardial glucose uptake when 
GSK-3 is inhibited in high-fat-fed mice and a correction of dia- 
betes in mice with a genetic deficiency of GSK-3β.(51) The latter 
study indicated that some of the effects of GSK-3 may also lie in 
the preservation of beta cell mass, therefore insulin secretory 
abilities.
These effects of GSK-3β therefore argue for a loop of reactions 
that, once set in motion, will exacerbate insulin resistance. Thus, 
insulin resistance causes inhibition of the inhibitory phosphoryla-
tion of GSK-3β by PKB/Akt, allowing GSK-3β to phosphorylate 
IRS-1 on serine residues which will further inhibit its activation 
leading to attenuated glut 4 translocation and  glucose uptake. 
Enhanced activity of GSK-3β will also phosphorylate GS thereby 
inhibiting glycogen formation with resultant elevation of glucose 
levels (Figure 1).
GSK-3 And MyocArdiAl contrActility                
The diabetic heart is characterised by reduced contractility 
independent of vascular disease. One of the role players in the 
changes in contractile function in diabetes, is the calcium pump 
(SERCA2) of the sarcoplasmic reticulum.  Total SERCA2 expres-
sion is decreased in hearts from diabetic mice,(52) while myo- 
cardial contractility in diabetic mice can be improved by cardiac-
specific over expression of SERCA2.(52,53) It has been reported 
that GSK-3β protein is a critical regulator of calcium handling in 
the heart.(54)  Using genetically manipulated mice that over express 
myocardial GSK-3β, Michael and co-workers showed that GSK-3β 
acts directly on the SERCA2 promoter to downregulate its 
expression, leading to systolic and diastolic dysfunction.(54) In 
addition, they reported impaired fractional shortening and re- 
duced +dP/dt values measured by echocardiographic methods. 
Cytosolic calcium was significantly elevated in diastole. This was 
coupled to lower mRNA levels and lower expression of SERCA2a 
protein.  In addition, the non-specific GSK-3 inhibitor LiCl, com-
pletely reversed the inhibition of SERCA2 mRNA expression. To 
underscore these results, King et al.,(55) using the protein phos-
phatase-1/inhibitor-2 complex to regulate the phosphorylation 
state of GSK-3, demonstrated increased SERCA2 expression. 
GSK-3 protein, by regulating SERCA2 expression, if elevated, may 
therefore be intimately involved in the contractile abnormalities 
of the diabetic heart.
GSK-3 And developMent of cArdiAc                      
hypertrophy
Diabetes is associated with left ventricular hypertrophy and dias-
tolic dysfunction which may eventually lead to clinical heart 
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failure.(56) Pre-clinical abnormalities of cardiac structure and func-
tion have been reported in diabetes of short duration(57) while 
echocardiographic studies pointed out the evidence of left ven-
tricular remodeling and demonstrated the existence of a discreet 
diabetic cardiomyopathy. (56)  
Cardiac hypertrophy can be either physiological or pathological. 
Pathological hypertrophy is associated with activation of neuro-
humoral pathways (endothelin I, angiotensin II, catecholamines) 
eventually leading to release of calcium from intracellular stores 
(mainly the sarcoplasmic reticulum).  This, in turn, will activate the 
calcium dependent phosphatase calcineurin, which regulates 
changes in gene expression associated with hypertrophy.(58) One 
of the more prominent transcription factors regulated by calcineu-
rin is nuclear factor of T-cells (NFAT).(59) These authors showed 
that cardiac hypertrophy is induced by calcineurin, which dephos-
phorylates NFAT-3, enabling it to translocate to the nucleus.   NFAT-
3 interacts with the cardiac zinc finger transcription factor GATA4, 
resulting in activation of gene transcription. GSK-3β can counter- 
act the activity of calcineurin by phosphorylating NFAT. Studies 
done with models of myocardial overexpression of GSK-3β have 
shown that GSK-3β is one of the most powerful antihypertrophic 
entities described thus far.(60,61)  Using LiCl, a non-specific inhibitor 
of GSK-3, Haq et al.(60) demonstrated that inhibition of GSK-3 
activity leads to features of cardiac hypertrophy.  This observation 
is underscored by the finding that deletion of GSK-3β in mice 
resulted in hypertrophic cardiomyopathy.(62) No live GSK-3β-/- pups 
were recovered in this study. The embryos had cardiac develop-
mental defects caused by cardiomyocyte hyperproliferation asso-
ciated with increased expression and nuclear translocation of 3 
regulators of proliferation – GATA4, cyclin D1 and c-Myc. It is 
also interesting to note that many hypertrophic stimuli inhibit 
GSK-3β, thereby removing its negative constraints on the 
development of hypertrophy. 
Besides the abovementioned inactivation of GSK-3β through phos-
phorylation on Ser9, it can also be inactivated by activation of the 
Wnt/frizzled pathway (Figure 2). This inactivation is apparently 
GSK-3 PROTEIN AND THE HEART
fiGure 2:  A schematic representation of  Wnt signalling in the context of GSK-3 involvement.
Wnt: ligand of the frizzled receptor, Dvl: disheveled is an intermediate protein relaying the signal from the receptor to a target protein,  GSK-3β: glycogen synthase kinase-3 beta, NFAT: nuclear 


































because of sequestration of the kinase rather than phosphoryla-
tion thereof. Blankestein and co-workers(58) reviewed the role of 
the Wnt/frizzled pathway in the inhibition of GSK-3β, arguing for 
a therapeutic anti-hypertrophic strategy by inhibiting Wnt/ 
frizzled signalling. 
It is generally accepted that there is re-expression of the fetal gene 
programme in the hypertrophic heart,(63) therefore, according to 
Blankestein, Wnt/frizzled signalling may be reactivated in the 
hypertrophic heart. They could show upregulation of frizzled-2 
expression in pressure overload hypertrophy in the rat(64) and 
demonstrated a causal relationship between this expression and 
the development of hypertrophy.(65) 
But, as highlighted by the result of Kerkela et al.,(62) inhibition of 
GSK-3 remains a 2-faced Janus.  The Wnt glycoproteins are essential 
for proper embryonic development due to their role in the 
regulation of cellular proliferation, differentiation, motility and 
polarity.(66-68) Already in 1995, Klein & Melton put forward a 
hypothesis that the effects of lithium on development of diverse 
organisms, was because of the inhibition of Wnt signalling by GSK-
3β.(69) Wnts act as ligands for the frizzled family of receptors. It 
elicits a response via the stabilisation of β−catenin, resulting in 
accumulation of the latter in the cytosol and nucleus where it 
results in activation of transcription of Wnt target genes.(66)  GSK-3β 
phosphorylates β−catenin, targeting it for ubiquitination and pro-
teasomal degradation.(68) Mutations in β−catenin at the residues 
that can be phosphorylated by GSK-3β is associated with develop-
ment of numerous types of cancer.(70)
GSK-3 And MyocArdiAl cell deAth or cell   
SurvivAl
It is well-recognised that, clinically, diabetes results in increased 
mortality and enhanced left ventricular dysfunction following myo-
cardial infarction after ischaemia/reperfusion.(71,72) Recently, Sena 
et al.(73) used cardiomyocyte-restricted insulin receptor knock out 
(CIRKO) mice to investigate possible mechanisms responsible for 
this. In a model of proximal coronary artery ligation to induce 
infarction, they followed changes in the heart over a 14 day period. 
Notably, they demonstrated enhanced left ventricular dysfunction 
coupled to accelerated mitochondrial dysfunction as well as 
attenuated expression of several proteins involved in glucose and 
fatty acid oxidation. In addition, SERCA2 expression was down 
regulated in the CIRKO mice.  
In the context of ischaemic heart disease, the concept of ischae- 
mic and pharmacological preconditioning has been intensively 
researched in the last decade. Ischaemic preconditioning refers to 
the phenomena whereby a series of short periods of myocardial 
ischaemia interspersed with reperfusion, has the ability to protect 
the heart against a successive longer period of ischaemia.(74) 
Because ischaemic preconditioning is still the most powerful 
endogenous protective mechanism that can be elicited in the 
heart, research centered on elucidating the mechanism thereof 
with the aim of duplicating it via pharmacological means. This was 
no easy matter as research demonstrated that different stimuli 
have the ability to mimic ischaemic preconditioning, leading to the 
search for a common denominator or end-effector. Since the 
balance between cell death and cell survival is central to ischaemic 
damage to the heart, research centered on signalling pathways 
that influence mitochondrial function and integrity. Some of these 
pathways implicated in preconditioning, are endogenous ligands 
released during ischaemia which would activate G-protein coupled 
receptors (adenosine, bradykinin, isoproterenol or opioids) that, 
in turn, activated a cascade of protein kinases (e.g. PKB, PKC, PKA, 
ERK, p38MAPK) that could influence mitochondrial integrity.(75-79) 
Following on the observation of Tong et al.(80) that preconditioning 
resulted in phosphorylation and inactivation of GSK-3β via a PI-
3Kinase mediated pathway, the work of Juhaszova et al.(81) took 
this one step further and demonstrated that the upstream effector 
that could integrate all the diverse signalling effects implicated in 
preconditioning, was GSK-3β. Using two of the new-generation 
GSK-3 inhibitors, Das and colleagues(82) demonstrated that pre-
treatment of hearts before ischaemia, with these inhibitors, was 
as protective as preconditioning. They furthermore confirmed 
the mitochondria as end-target of this protection. According to 
their results, GSK inhibition decreased mitochondrial membrane 
potential with less calcium loading and less oxygen radical pro-
duction, thereby conferring protection. In addition, mitochondrial 
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affinity for the anti-apoptotic protein Bcl-2 increased, with more 
Bcl-2 associated with mitochondria in the presence of GSK-3 
inhibition, inferring a pro-apoptotic role for GSK-3. This conclusion 
is substantiated by the work of Hirotani et al.,(83) using a transgenic 
mouse with cardiac-specific expression of a dominant negative 
form of GSK-3β, who demonstrated accumulation of the anti-
apoptotic molecule MCL-1 in these animals. This, as well as the 
anti-apoptotic effects of GSK-3 inhibition, could be abolished by 
knock down of MCL-1 with small inhibitory RNA molecules. All 
these effects could therefore contribute to the observed car-
dioprotective effect of the GSK inhibitors. It must be kept in mind 
that a pro-apoptotic role for GSK-3 would also argue for an 
inhibition of hypertrophy, as discussed previously.
As mentioned before, there are studies demonstrating upregula-
tion of expression and higher activity (therefore more of the 
less phosphorylated form) of GSK-3 protein in skeletal muscle of 
type 2 diabetic patients and in adipose tissues of obese diabetic 
mice.(38,39) Investigating the protection afforded by post-condi-
tioning (where, in contrast to pre-conditioning, the short, repe- 
titive episodes of ischaemia/reperfusion are implemented imme-
diately at the onset of reperfusion to elicit protection)(84) Wagner 
et al. (2008) could not elicit post-conditioning in a rat model with 
metabolic syndrome.(85) This was accompanied by a failure of 
post-conditioning to result in phosphorylation and inhibition of 
GSK-3β.
On the other hand, Nishino et al.,(86) using a mouse line lacking 
the critical N-terminal serine within myocardial GSK-3β (Ser9) as 
well as Ser21 in GSK-3β, still found protection via preconditioning 
in the isolated, perfused heart subjected to ischaemia, excluding 
a role for inhibition of GSK-3 in this phenomenon in the mouse 
heart as opposed to the findings of Juhaszova in the rat heart.(81) 
GSK-3 inhibition in the heArt –                            
A tuG-of-WAr?
At this stage, it would therefore seem as if the vote on inhibition 
of GSK-3 as a therapeutic intervention, especially with regards to 
the heart, is too close to call.
As mentioned, the kinase GSK-3, is involved in not only the 
regulation of glycogen synthesis and the development of insulin 
resistance and type 2 diabetes, but is implicated in an array of 
biological processes including cell death and survival and deve-
lopmental patterning. It is also associated with the development of 
various neurodegenerative abnormalities e.g. Alzheimers disease, 
schizophrenia and possibly Huntington’s disease. It is further- 
more implicated in the development of different forms of cancer, 
to name but a few.(87) From this it can be deduced that the inhibi-
tion of GSK-3 has a very high therapeutic potential in a number of 
different human diseases.  
As is indicated by the preceding discussion, in the field of cardi-
ology, the list of “positives” of GSK-3 inhibition will probably 
outweigh that of the “negatives”. Inhibition of GSK-3 signalling 
will inhibit apoptosis, and therefore reduce the damage caused 
by myocardial ischaemia. It is protective in heart failure. It im- 
proves insulin sensitivity not only by enhancing hepatic glycogen 
synthesis and reducing hepatic glucose output, but also improves 
whole body glucose tolerance by the enhancement of glut 4 pro-
tein levels in the cell membranes of skeletal muscle cells. Inhibi- 
tion of GSK-3 should improve contractile function in states of 
insulin resistance via upregulation of SERCA2 expression and it 
should also have anti-inflammatory effects via inhibition of activa-
tion of NF-κB.(87) The latter speculation is substantiated by one 
report showing that the GSK-3 inhibitor TDZD-8, when given to 
ex vivo perfused rat hearts at the start of reperfusion after ischae-
mia, presented with reduced NF-κB activation coupled to smaller 
infarct size and reduced apoptosis.(88) In addition, the work of 
Sato et al. (2004) demonstrated that a specific inhibitor of GSK-3 
has the ability to maintain self-renewal and pluripotency in human 
and mouse embryonic stem cells.(89) This was probably because 
of increased β-catenin activity from activation of the Wnt signalling 
pathway.  Following on this, Tseng et al. (2006) published results 
to show that inhibition of GSK-3 was also able to raise β-catenin 
activity in neonatal rat cardiomyocytes.(90) GSK-3 inhibition in 
these cells induced cell cycle entry at the S-phase and resulted in 
cell division. They tested whether this would hold true in adult 
rat cardiomyocytes and showed that GSK-3 inhibition also induced 
adult rat and mammalian cardiomyocytes to dedifferentiate and 




















undergo mitosis.  In the heart, with its lack of proliferative potential 
and formation of scar tissue after infarction, treatment able to in-
duce proliferation and regeneration, will have enormous potential. 
On the down side of inhibition of GSK-3 lies the fact that these 
inhibitors are mostly non-specific, that their use may lead to 
development of cardiac hypertrophy because of a lift on the 
inhibition of calcineurin and furthermore, that GSK-3 inhibition 
may be teratogenic.  In other tissue, inhibition of GSK-3 may in- 
duce different forms of cancer e.g. colorectal cancers have defects 
in elements of the Wnt pathway that lead to accumulation of 
β-catenin(91) that will be exacerbated by GSK-3 inhibition.  How-
ever, available data do not show enhanced incidence of cancer in 
patients after long-term treatment with lithium.(92) Furthermore, 
under some circumstances, GSK-3 inhibitors might be useful in 
treating  specific cancers.(93) 
Currently, more than 30 different GSK-3 inhibitors have been 
described.(2,94) As summarised by these reviews, they have a diver-
sity of structure and size but most of them are small in order to 
reach GSK-3 where it is embedded in protein complexes, and 
most of them act by competing with ATP in the ATP-binding site 
of the kinase. Unfortunately, even the inhibitors described as 
more selective,(10) will also inhibit other protein kinases.(94) All of 
the available GSK-3 inhibitors will lead to elevated β-catenin 
levels.(68)  Despite this, no deleterious effects have yet been 
reported in rodent studies.  However, it seems that there is an 
absence of long-term studies with GSK-3 inhibitor treatment in 
rodent models of disease. Most of the negative effects have been 
reported using genetically modified animals.  At the moment, 
the bottom line is still that, in the words of Sugden et al. (2008): 
“we just do not know whether to inhibit or activate GSK-3, or 
simply not to interfere!”(8)
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